共 13 条
[1]
Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease. Selwyn AP,Kinlay S,Libby P,et al. Circulation . 1997
[2]
Effect of statin therapy on Creactive protein levels: the pravastatin inflammation CRP evaluation(PRINCE): a randomized trial and cohort study. Albert MA,Danielson E,Rifai N,et al. The Journal of The American Medical Association . 2001
[3]
Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Ridker PM,Rifai N,Lowenthal SP,et al. Circulation . 2001
[4]
Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Lacostc L,Larn JYT,Hung J,et al. Circulation . 1995
[5]
Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. Kaesemeyer WH,Caldwell RB,Huang JZ,et al. Journal of the American College of Cardiology . 1999
[6]
Statins inhibit tissue factor in cultured human macrophages. Colli S,Eligini S,Lalli M,et al. Arteriosclerosis and Thrombosis . 1997
[7]
HMG-CoA reductase inhibition promotes endothelial cell nitric oxide synthase activation through a decrease in caveolin abundance. Feron O,Dessy C,Desager JP,et al. Circulation . 2000
[8]
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes:the MIRACL study: a randomized controlled trial. Schwartz GG,Olsson AG,Ezekowitz MD,et al. The Journal of The American Medical Association . 2001
[9]
Atherosclerosis[P]. DONG CHUNMING;GOLDSCHMIDT PASCAL J.中国专利:US2008095751A1,2008-04-24
[10]
Simvastatin, an HMG-Coenzyme A reductase inhibitor improves endothelial function within 1 month. O’Driscoll G,Green D,Taylor RR,et al. Circulation . 1997